A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study

C-Met receptor is frequently overexpressed in multiple cancers, driving tumor invasiveness, metastasis, and therapy resistance. Although amivantamab has received clinical approval as a c-Met inhibitor, its large molecular size and lack of intrinsic cytolytic activity limit its broader therapeutic application, underscoring the need for next-generation dual-mechanism agents. To address this, we designed, produced, and characterized a novel immunotoxin, SM1, comprising an anti-c-Met scFv derived from amivantamab fused to the cytolytic peptide melittin via flexible (G 4 S) 3 linkers. Among four computationally designed models, SM1 exhibited the most favorable binding free energy toward c-Met and was selected for experimental validation. SM1 was successfully expressed in Escherichia coli C41 (DE3) as a SUMO fusion protein, while the scFv without melittin (S1) was expressed in BL21 (DE3). Both proteins were overexpressed as inclusion bodies, solubilized using sarcosyl, and purified for functional characterization. Cell-ELISA showed stronger apparent cellular binding of both constructs to c-Met-overexpressing MKN-45 cells than to HT-29 cells, consistent with c-Met expression levels, while indicating that melittin fusion did not substantially affect scFv binding. To assess whether the melittin domain retained its lytic activity after fusion, the antibacterial activity of SM1 was evaluated against E. coli JM109, and the observed growth inhibition confirmed the retention of melittin-associated lytic activity in the fusion construct. In cytotoxicity assays, SM1 exhibited greater activity than S1 against both MKN-45 and HT-29 cells, with the strongest response observed in MKN-45 cells, while HEK-293 viability remained above 80% under the tested conditions. This selective cytotoxicity was accompanied by limited hemolytic activity, with both constructs showing less than 10% hemolysis at the highest concentration tested of 200 µM. Flow cytometry analysis further revealed potent apoptosis induction (97.03%) and extensive Sub-G1 accumulation in MKN-45 cells, with markedly lower effects in HEK-293 cells (9.22%), confirming target-dependent cytotoxicity. These findings demonstrate the preferential cytotoxicity of SM1 toward c-Met-expressing cancer cells and support its potential as a dual-mechanism immunotoxin for targeted therapy of c-Met-driven malignancies.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-17
DOI
https://doi.org/10.1038/s41598-026-80997-x
Primary Topic
Toxin Mechanisms and Immunotoxins
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study

Bahareh Dabirmanesh, Khosro Khajeh, Zahra Poordad
Scientific Reports
Toxin Mechanisms and Immunotoxins
article

A scFv-based immunotoxin for selective targeting and cytotoxicity against c-Met-overexpressing cancer cells: an integrated in silico and in vitro study

Bahareh Dabirmanesh, Khosro Khajeh, Zahra Poordad
article en

Abstract

C-Met receptor is frequently overexpressed in multiple cancers, driving tumor invasiveness, metastasis, and therapy resistance. Although amivantamab has received clinical approval as a c-Met inhibitor, its large molecular size and lack of intrinsic cytolytic activity limit its broader therapeutic application, underscoring the need for next-generation dual-mechanism agents. To address this, we designed, produced, and characterized a novel immunotoxin, SM1, comprising an anti-c-Met scFv derived from amivantamab fused to the cytolytic peptide melittin via flexible (G 4 S) 3 linkers. Among four computationally designed models, SM1 exhibited the most favorable binding free energy toward c-Met and was selected for experimental validation. SM1 was successfully expressed in Escherichia coli C41 (DE3) as a SUMO fusion protein, while the scFv without melittin (S1) was expressed in BL21 (DE3). Both proteins were overexpressed as inclusion bodies, solubilized using sarcosyl, and purified for functional characterization. Cell-ELISA showed stronger apparent cellular binding of both constructs to c-Met-overexpressing MKN-45 cells than to HT-29 cells, consistent with c-Met expression levels, while indicating that melittin fusion did not substantially affect scFv binding. To assess whether the melittin domain retained its lytic activity after fusion, the antibacterial activity of SM1 was evaluated against E. coli JM109, and the observed growth inhibition confirmed the retention of melittin-associated lytic activity in the fusion construct. In cytotoxicity assays, SM1 exhibited greater activity than S1 against both MKN-45 and HT-29 cells, with the strongest response observed in MKN-45 cells, while HEK-293 viability remained above 80% under the tested conditions. This selective cytotoxicity was accompanied by limited hemolytic activity, with both constructs showing less than 10% hemolysis at the highest concentration tested of 200 µM. Flow cytometry analysis further revealed potent apoptosis induction (97.03%) and extensive Sub-G1 accumulation in MKN-45 cells, with markedly lower effects in HEK-293 cells (9.22%), confirming target-dependent cytotoxicity. These findings demonstrate the preferential cytotoxicity of SM1 toward c-Met-expressing cancer cells and support its potential as a dual-mechanism immunotoxin for targeted therapy of c-Met-driven malignancies.

Scientific Reports
Tarbiat Modares University (IR)
Tarbiat Modares University, National Institute for Medical Research Development
Good health and well-being
Toxin Mechanisms and Immunotoxins
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon